A cephalosporin antibiotic
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Cefepime (hydrochloride hydrate)

Item No. 23633

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
1-[[(6R,7R)-7-[[(2Z)-2-(2-amino-4-thiazolyl)-2-(methoxyimino)acetyl]amino]-2-carboxy-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-en-3-yl]methyl]-1-methyl-pyrrolidinium, monochloride, monohydrochloride, monohydrate
CAS Number
123171-59-5
Molecular Formula
C19H25N6O5S2 • Cl [HCl] [H2O]
Formula Weight
571.5
Purity
≥90%
Formulation (Request formulation change)
A crystalline solid
Solubility(Learn about Variance in Solubility)
DMF: 0.1 mg/mlDMSO: 0.2 mg/mlPBS (pH 7.2): 10 mg/ml
λmax
238, 264 nm
SMILES
O=C(O)C1=C(C[N+]2(C)CCCC2)CS[C@@]([C@@H]3NC(/C(C4=CSC(N)=N4)=N\OC)=O)([H])N1C3=O.[Cl-].Cl.O
InChi Code
InChI=1S/C19H24N6O5S2.2ClH.H2O/c1-25(5-3-4-6-25)7-10-8-31-17-13(16(27)24(17)14(10)18(28)29)22-15(26)12(23-30-2)11-9-32-19(20)21-11;;;/h9,13,17H,3-8H2,1-2H3,(H3-,20,21,22,26,28,29);2*1H;1H2/b23-12-;;;/t13-,17-;;;/m1.../s1
InChi Key
LRAJHPGSGBRUJN-OMIVUECESA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    250 mg

    $40

    Add

    500 mg

    $70

    Add

    1 g

    $123

    Add

    5 g

    $488

    Add
    Cayman Chemical
    Neutrophil Biology Wall Poster

    Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.

    DOWNLOAD NOW
    Product Description

    Cefepime is a broad-spectrum cephalosporin antibiotic that inhibits the growth of Gram-positive and Gram-negative bacteria.1,2 It inhibits the growth of some clinical isolates of Corynebacterium, Streptococcus, and Staphylococcus (MIC90s = 0.03-8 μg/ml), but does not inhibit the growth of methicillin-resistant S. aureus (MRSA) or S. haemolyticus (MIC50s = >128 μg/ml).1 Cefepime inhibits the growth of some Citrobacter, Enterobacter, Klebsiella, Salmonella, Serratia, Shigella, and enteric bacilli species in addition to P. mirabilis and E. coli clinical isolates (MIC90s = ≤0.12-2 μg/ml).2 It also inhibits the growth of E. coli and Klebsiella strains that produce extended-spectrum β-lactamase (ESBL; MIC90s = 4 and 8 μg/mL, respectively) and of indole-positive Proteae (MIC90 = 0.25 μg/ml). Cefepime inhibits the growth of pneumococci strains (MICs = 0.5-2 mg/l) in vitro and in vivo in a mouse model of peritonitis (ED50s = 0.6-1.14 mg/kg).3 Formulations containing cefepime have been used in the treatment of a variety of bacterial infections.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kessler, R.E., and Fung-Tomc, J. Susceptibility of bacterial isolates to β-lactam antibiotics from U.S. clinical trials over a 5-year period. Am. J. Med. 100(6A), 13S-19S (1996).

    2. Sader, H.S., Fritsche, T.R., and Jones, R.N. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: Results from the SENTRY Antimicrobial Surveillance Program (1998-2003). Diagn. Microbiol. Infect. Dis. 52(3), 265-273 (2005).

    3. Knudsen, J.D., Fuursted, K., Frimodt-Møller, N., et al. Comparison of the effect of cefepime with four cephalosporins against pneumococci with various susceptibilities to penicillin, in vitro and in the mouse peritonitis model. J. Antimicrob. Chemother. 40(5), 679-686 (1997).